American SIDS Institute Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2000
NCT00482781
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

American SIDS Instittute | American SIDS Institute

Active Ingredients

Drugs in Phase 3 Trials (1)

caffeine (2 trials)

Drugs in Other Trials (1)

DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine (Pediarix) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypoxia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2